The Effect of Probiotics on Non Alcoholic Fatty Liver Disease

Status Terminated

Clinical Trial Summary

Nonalcoholic Fatty Liver Disease (NAFLD) has been suggested to be the most common cause of chronic liver disease in the general population in the Western World. In advanced stages of NAFLD, steatohepatitis (NASH) develops characterized by: steatosis, inflammation, and fibrosis progressing to cirrhosis in some patients. The knowledge of the role of small intestinal bacterial overgrowth (SIBO) in the pathogenesis of NASH has led to the proposal of probiotics as a therapeutic strategy for this disorder.

Clinical Trial Description

Probiotics may interfere with the development of NASH by several mechanisms. Data from an uncontrolled clinical trial in NASH patients show promising results, with improvement of liver enzymes in treated patients.

RESEARCH GOALS:

A. To assess the degree of SIBO in NAFLD patients vs. healthy controls. B. To evaluate the effect of probiotics vs. placebo on SIBO in NAFLD patients. C. To evaluate the effect of probiotics vs. placebo on disease severity (inflammation, steatosis, and fibrosis) in NAFLD patients. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00808990
Study type	Interventional
Source	Rabin Medical Center
Contact
Status	Terminated
Phase	Phase 1
Start date	February 2013
Completion date	September 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02798861` - Controlled Attenuation Parameter (CAP) in Liver Allografts
Completed	`NCT01968395` - Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure	Phase 4
Completed	`NCT01437969` - Pharmacogenomics Study on IL28B Genetic Variants in Italian Patients With HCV Infection naïve to Treatment.
Recruiting	`NCT00155376` - Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography	Phase 4
Recruiting	`NCT00172705` - Quantitative Diagnosis of Fatty Liver by Dual Energy CT Technique	N/A
Completed	`NCT04185454` - Estimation of Minimum Efficacy Daily Dose of Jarlsberg Cheese	N/A
Completed	`NCT02506335` - Liver Function Measured by HepQuant-SHUNT in the Prediction of Outcomes in Patients With Heart Disease	Early Phase 1
Completed	`NCT02520609` - Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease
Completed	`NCT02306018` - Evaluation of a New Calibrated Pulse Wave Analysis Method(EV1000™/volumeView™) for Cardiac Output Monitoring in Adult Liver Transplantation	N/A
Completed	`NCT01988753` - Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases
Completed	`NCT01970904` - Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients	N/A
Terminated	`NCT00741117` - Conjugated Hyperbilirubinemia and Pulse Oximetry	N/A
Enrolling by invitation	`NCT01483248` - Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis	Phase 1/Phase 2
Completed	`NCT00074386` - Kidney and Liver Transplantation in People With HIV	N/A
Completed	`NCT00245830` - Ischemic Preconditioning of Liver in Cadaver Donors	N/A
Completed	`NCT02329821` - Change of Lactate Concentration During Hartmann Solution Infusion for Hepatic Resection	N/A
Completed	`NCT01650181` - Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis	Phase 4
Completed	`NCT01303549` - Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients	Phase 4
Completed	`NCT00799851` - A Randomized Controlled Trial Comparing Band Ligation and Cyanoacrylate Injection for Esophageal Varices	Phase 4
Completed	`NCT00058890` - Gabapentin to Treat Itch in Patients With Liver Disease	Phase 3